<DOC>
	<DOCNO>NCT00723710</DOCNO>
	<brief_summary>Patients malignant melanoma undergone surgery receive adjuvant treatment high-dose Intron A one year . The objective study maximize treatment compliance proactive management side effect day-to-day healthcare setting .</brief_summary>
	<brief_title>Effect Proactive Management Side Effects Treatment Compliance Malignant Melanoma Patients High-dose Intron A Therapy ( Study P04600 )</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>Signed informed consent Age &gt; 18 year Confirmed melanoma Patient prescribe Intron A therapy HighRisk Stage II &amp; III Melanoma Intron A therapy start within 70 day surgery ( additional 15 day may grant sponsor upon write approval ) Proper contraception male female subject female partner ( ) male study subject Metastatic disease time diagnosis Other malignancy History non compliance therapy Pregnancy breast feed Previous Intron A therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
</DOC>